NextBio

Help
Description: Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases. It was removed from the United States market in 1998 and the Canadian market in 1996 as a psoriasis medication, due to the high risk of birth defects. Etretinate is now used to treat T-cell lymphomas. It also appears to inhibit NADH oxidase activity.
Drug Type: Small Molecule; Withdrawn
Pharmacology: The active metabolite responsible for etretinate's effects, acitretin, is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling.
Mechanism of Action: The mechanism of action of the active metabolite, acitretin, is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells.
Indication: For the treatment of severe psoriasis in adults.
Half Life: In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.
View Complete Description



Data Correlations | 5 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
RXRG 100 100
RARG 99 99
RXRB 99 99
RXRA 98 98
RARB 98 98
RARA 97 97
View Top Genes
Biogroups category icon Biogroups
Score Help
Steroid hormone receptor 100 100
Nuclear Receptors 100 100
Zinc finger, nuclear hormone recept… 99 99
Nuclear hormone receptor, ligand-bi… 99 99
Nuclear hormone receptor, ligand-bi… 99 99
RAR-RXR Pathway 99 99
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving etretinate.

View All Author iconAuthors
  • Mariko Seishima
  • Yoshinao Shibuya
  • Atsuyuki Igarashi
  • Akira Ohkawara
  • M Mashiko
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Bristol-Myers Squibb
  • Rockefeller University
  • Children's Hospital & Research Center Oakland
  • Hoffmann-La Roche
View All Affiliations icon Organizations
  • Ogaki Municipal Hospital
  • Yamaguchi University School of Medicine
  • Sungkyunkwan University School of Medicine
  • Hoshigaoka Koseinenkin Hospital
  • Aichi Medical University School of Medicine

Clinical Trials | 18 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “etretinate”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “etretinate”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio